PharmTech4d
FDA Approves AbbVie Therapy for Adults with Advanced Parkinson’s Disease
Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.
AbbVie: Expect A Beat-And-Raise Q3 2024
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
FDA approves Vyalev for advanced Parkinson's disease
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
Spokane woman gets back her ‘normal life’ from newly approved Parkinson’s disease treatment
Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...
HealthDay on MSN5d
FDA Approves Vyalev for Advanced Parkinson Disease
The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...